Vietnam's pharmaceutical industry is entering a period of significant transformation as the country strengthens domestic production of active pharmaceutical ingredients (APIs), reduces dependence on imported raw materials and positions itself as an increasingly important pharmaceutical manufacturing hub in Southeast Asia.
According to IMARC Group, Vietnam's Active Pharmaceutical Ingredients (API) Market reached US$1.053 billion in 2025 and is forecast to grow to US$1.910 billion by 2034. The market is being supported by rising pharmaceutical consumption, expansion of generic drug manufacturing and increasing investment across the country's life sciences sector.
Active pharmaceutical ingredients are the biologically active substances responsible for the therapeutic effect of medicines. They form the foundation of every pharmaceutical product, whether chemically synthesised or biologically derived, and are essential for branded medicines, generic drugs, biosimilars and advanced therapies.
The market encompasses:
- Synthetic APIs
- Biotech APIs
- Generic APIs
- Innovative APIs
- High-potency APIs (HPAPIs)
- Oncology APIs
- Cardiovascular APIs
- Anti-infective APIs
- Diabetes APIs
- Contract API manufacturing (CDMO and CMO services)
Several structural trends are supporting long-term growth across Vietnam.
The country's pharmaceutical market continues to expand as healthcare expenditure rises and demand increases for treatments targeting chronic diseases including diabetes, cardiovascular disease, cancer and respiratory disorders. As patents expire on major medicines, manufacturers are increasing production of generic drugs, creating sustained demand for high-quality APIs. At the same time, Vietnam is seeking to strengthen pharmaceutical self-sufficiency and reduce reliance on imported ingredients through greater investment in domestic manufacturing capabilities.
Government policy is also encouraging industry development. Vietnam has identified pharmaceutical manufacturing as a strategic industry, with initiatives aimed at improving local production capacity, attracting foreign investment and strengthening supply chain resilience. These efforts align with broader regional trends as global pharmaceutical companies diversify sourcing strategies and seek alternatives to concentrated manufacturing locations.
The country's growing role in pharmaceutical manufacturing is creating opportunities across the API value chain. Investment is increasing in research and development, quality management, regulatory compliance and contract manufacturing services, while domestic companies are expanding capabilities to meet international Good Manufacturing Practice (GMP) standards.
Globally, the API market continues to grow steadily. IMARC Group estimates the Global Active Pharmaceutical Ingredients Market reached US$256.4 billion in 2025 and is expected to expand to US$376.2 billion by 2034, driven by increasing pharmaceutical consumption, growth in biologics and biosimilars, expanding CDMO services and continued innovation across therapeutic areas. Asia-Pacific is forecast to remain the fastest-growing regional market.
Technology is also reshaping API manufacturing. Continuous manufacturing, process analytical technology (PAT), digital quality management systems and artificial intelligence are improving production efficiency while reducing waste and accelerating process optimisation. High-potency APIs are becoming increasingly important as oncology and precision medicine continue to expand, while biologic APIs are driving investment in advanced biopharmaceutical manufacturing facilities.
Vietnam is well positioned to benefit from these trends. The country's competitive manufacturing costs, skilled workforce, strategic location within ASEAN and expanding pharmaceutical ecosystem make it an increasingly attractive destination for pharmaceutical investment. As multinational companies diversify supply chains and regional demand for medicines continues to increase, Vietnam has the opportunity to strengthen its position within the global pharmaceutical manufacturing network.
Leading companies operating across the global API market include Lonza, WuXi AppTec, Pfizer CentreOne, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Aurobindo Pharma, Sun Pharmaceutical Industries, Divi's Laboratories, Cipla, Boehringer Ingelheim, Viatris, Cambrex and Recipharm, all of which continue to invest in advanced manufacturing technologies, biologics, high-potency APIs and contract development and manufacturing services.
As Vietnam continues to modernise its pharmaceutical industry and strengthen domestic manufacturing, the API sector is expected to become an increasingly strategic component of the country's healthcare economy. For API manufacturers, CDMOs, pharmaceutical equipment suppliers, process technology providers, quality assurance specialists and life sciences investors, Vietnam represents one of Southeast Asia's most promising long-term growth markets.
